Cormorant Asset Management, LP - Jun 23, 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role: 10%+ Owner
Signature: /s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner, By: Bihua Chen, Managing Member
Stock symbol: GLUE
Transactions as of: Jun 23, 2021
Transactions value $: $0
Form type: 3
Date filed: 6/23/2021, 06:09 PM
Previous filing: Jun 23, 2021
Next filing: Jun 24, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	GLUE	Series B Convertible Preferred Stock							Jun 23, 2021	Common Stock	2.12M		See Footnotes	F1, F2, F3
holding	GLUE	Series C Convertible Preferred Stock							Jun 23, 2021	Common Stock	478K		See Footnotes	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of Series B and Series C Convertible Preferred Stock are convertible at any time at the holder's election, without payment of additional consideration. Such shares have no expiration date but are expected to convert into Common Stock automatically upon the closing of the Issuer's initial public offering.
F2	Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III") and a managed account (the "Account"). Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II") and Cormorant Private Healthcare GP III, LLC ("GP III") serve as General Partner of the Master Fund, Fund II and Fund III, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II and GP III. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 3 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
F3	Shares of Series B Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 226,242 shares held by the Master Fund, (ii) 843,577 shares held by Fund II and (iii) 1,054,524 shares held by Fund III.
F4	Shares of Series C Convertible Preferred Stock reported herein represent, on an as-converted basis, (i) 104,650 shares held by the Master Fund, (ii) 364,725 shares held by Fund III, and (iii) 8,482 shares held by the Account.